CY1106828T1 - Χρηση μορφολινολης για την αντιμετωπιση σεξουαλικης δυσλειτουργιας - Google Patents
Χρηση μορφολινολης για την αντιμετωπιση σεξουαλικης δυσλειτουργιαςInfo
- Publication number
- CY1106828T1 CY1106828T1 CY20071101117T CY071101117T CY1106828T1 CY 1106828 T1 CY1106828 T1 CY 1106828T1 CY 20071101117 T CY20071101117 T CY 20071101117T CY 071101117 T CY071101117 T CY 071101117T CY 1106828 T1 CY1106828 T1 CY 1106828T1
- Authority
- CY
- Cyprus
- Prior art keywords
- morpholinol
- sexual dysfunction
- salts
- disease
- compound
- Prior art date
Links
- 201000001880 Sexual dysfunction Diseases 0.000 title abstract 2
- 231100000872 sexual dysfunction Toxicity 0.000 title abstract 2
- OURXRFYZEOUCRM-UHFFFAOYSA-N 4-hydroxymorpholine Chemical compound ON1CCOCC1 OURXRFYZEOUCRM-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 241000208125 Nicotiana Species 0.000 abstract 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- RCOBKSKAZMVBHT-TVQRCGJNSA-N radafaxine Chemical compound C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1 RCOBKSKAZMVBHT-TVQRCGJNSA-N 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9801230.5A GB9801230D0 (en) | 1998-01-21 | 1998-01-21 | Pharmaceutically active morpholinol |
| US7218098P | 1998-01-22 | 1998-01-22 | |
| PCT/US1999/001134 WO1999037305A1 (en) | 1998-01-21 | 1999-01-20 | Pharmaceutically active morpholinol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106828T1 true CY1106828T1 (el) | 2012-05-23 |
Family
ID=26312986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071101117T CY1106828T1 (el) | 1998-01-21 | 2007-08-31 | Χρηση μορφολινολης για την αντιμετωπιση σεξουαλικης δυσλειτουργιας |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6274579B1 (enExample) |
| EP (2) | EP1047428B1 (enExample) |
| JP (1) | JP2002501025A (enExample) |
| KR (1) | KR100568063B1 (enExample) |
| CN (2) | CN1203858C (enExample) |
| AP (1) | AP1229A (enExample) |
| AT (1) | ATE365042T1 (enExample) |
| AU (1) | AU755536B2 (enExample) |
| BR (1) | BR9907203A (enExample) |
| CA (1) | CA2318268A1 (enExample) |
| CY (1) | CY1106828T1 (enExample) |
| DE (1) | DE69936335T2 (enExample) |
| DK (1) | DK1047428T3 (enExample) |
| EA (1) | EA002410B1 (enExample) |
| EE (1) | EE04452B1 (enExample) |
| ES (1) | ES2288012T3 (enExample) |
| HR (2) | HRP20000494B1 (enExample) |
| HU (1) | HUP0100900A3 (enExample) |
| ID (1) | ID26334A (enExample) |
| IL (2) | IL137346A0 (enExample) |
| IS (1) | IS2494B (enExample) |
| NO (2) | NO326878B1 (enExample) |
| NZ (3) | NZ505809A (enExample) |
| PL (1) | PL193622B1 (enExample) |
| PT (1) | PT1047428E (enExample) |
| SG (1) | SG115489A1 (enExample) |
| SK (1) | SK10912000A3 (enExample) |
| TR (1) | TR200002126T2 (enExample) |
| WO (1) | WO1999037305A1 (enExample) |
| YU (1) | YU67102A (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098206B2 (en) * | 1998-01-21 | 2006-08-29 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6998400B2 (en) * | 1998-01-22 | 2006-02-14 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| WO1999038503A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmacological uses of optically pure (+)-bupropion |
| US6855820B2 (en) | 1999-01-20 | 2005-02-15 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6734213B2 (en) | 1999-01-20 | 2004-05-11 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6342496B1 (en) * | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| AU7750100A (en) * | 1999-10-13 | 2001-04-23 | Glaxo Group Limited | Method for the treatment of obesity |
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| CA2365428C (en) * | 2000-12-21 | 2008-10-21 | Brasscorp Limited | Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing |
| US6979104B2 (en) | 2001-12-31 | 2005-12-27 | R.J. Doran & Co. LTD | LED inspection lamp |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| AU2003231788B2 (en) * | 2002-05-17 | 2008-09-11 | Duke University | Method for treating obesity |
| US7384941B2 (en) * | 2002-08-23 | 2008-06-10 | Eli Lilly And Company | 2-(phenoxymethyl)-and 2-(phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
| GB0219687D0 (en) * | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
| KR101167579B1 (ko) * | 2003-04-29 | 2012-07-27 | 오렉시젠 세러퓨틱스 인크. | 체중감량용 조성물 |
| JP2007509856A (ja) * | 2003-10-27 | 2007-04-19 | スミスクライン ビーチャム コーポレーション | （＋）−（２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノール、その塩および溶媒和物を調製するための酵素触媒動的速度論分割方法 |
| GB0325055D0 (en) * | 2003-10-27 | 2003-12-03 | Smithkline Beecham Corp | New process |
| GB0326148D0 (en) * | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
| GB0327195D0 (en) * | 2003-11-21 | 2003-12-24 | Smithkline Beecham Corp | Novel use |
| GB0327619D0 (en) * | 2003-11-27 | 2003-12-31 | Smithkline Beecham Corp | New use |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| BRPI0506829A (pt) | 2004-01-13 | 2007-05-29 | Univ Duke | composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso |
| MXPA06012685A (es) * | 2004-05-03 | 2007-01-16 | Univ Duke | Composiciones para afectar la perdida de peso. |
| FI117283B (fi) | 2005-02-04 | 2006-08-31 | Kone Corp | Hissijärjestelmä |
| PT2135603E (pt) | 2005-11-22 | 2013-04-03 | Orexigen Therapeutics Inc | Composições e métodos para aumentar a sensibilidade à insulina |
| WO2007079470A2 (en) | 2006-01-03 | 2007-07-12 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| WO2008060964A2 (en) | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
| DE602007005402D1 (de) | 2006-11-09 | 2010-04-29 | Orexigen Therapeutics Inc | Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht |
| US20090075994A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched radafaxine |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| CA2758774C (en) | 2009-04-15 | 2015-02-03 | Research Triangle Institute | Monoamine reuptake inhibitors |
| ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
| CA2800219C (en) | 2010-05-21 | 2019-03-12 | Research Triangle Institute | 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence |
| CA2800220C (en) | 2010-05-21 | 2019-04-30 | Research Triangle Institute | Phenylmorpholines and analogues thereof |
| US9510405B2 (en) | 2011-06-30 | 2016-11-29 | Schneider Electric Industries Sas | Dual power SMPS for a modular lighting system |
| CN102670617B (zh) * | 2012-04-13 | 2013-03-20 | 湖南大学 | 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用 |
| PL4104824T3 (pl) | 2012-06-06 | 2025-11-12 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
| CN105949142B (zh) * | 2016-05-21 | 2018-03-27 | 南华大学 | 具有抗抑郁活性的单一手性化合物及其制备方法和应用 |
| RU2763728C1 (ru) * | 2021-06-17 | 2021-12-30 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US170430A (en) * | 1875-11-30 | Improvement in furnaces for heating steel in tempering | ||
| GB8417170D0 (en) * | 1984-07-05 | 1984-08-08 | Wellcome Found | Heterocyclic pharmaceutical compounds |
| GB9108629D0 (en) | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
-
1999
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en not_active Ceased
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
-
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
-
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
-
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
-
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
-
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200002126T2 (tr) | Farmasötik olarak aktif morfolinol | |
| JP2002501025A5 (enExample) | ||
| AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| AU2002314914A1 (en) | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases | |
| ATE378043T1 (de) | Polyhydroxylierte aromatischen verbindungen für die behandlung von amyloidosis und alpha- synuclein fibril krankheiten | |
| CY1106697T1 (el) | Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων | |
| BR0110487A (pt) | Composição farmacêutica e método de tratamento de doenças de disfunção cognitiva em um mamìfero | |
| GB0225475D0 (en) | Therapeutic agents | |
| BR0207526A (pt) | Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral | |
| ATE426405T1 (de) | Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| GB0005251D0 (en) | Therapeutic compounds | |
| BR0007424A (pt) | Composto, composição farmacêutica, método para o tratamento de depressão em um paciente necessitando do mesmo, e, processo para a preparação de um composto | |
| GB0318447D0 (en) | Therapeutic agents | |
| ATE221781T1 (de) | Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms | |
| BR0103169A (pt) | Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd) | |
| BR9913072A (pt) | Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia | |
| MXPA05012955A (es) | Composiciones farmaceuticas de atorvastatina. | |
| PL338673A1 (en) | Application of fanquinone in treating alzheimer disease | |
| NO20005059L (no) | Nye behandlinger for nervøse lidelser | |
| DE69917005D1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
| RU94041028A (ru) | Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция | |
| BRPI0412438A (pt) | novas amidas aza-heterocìclicas úteis para o tratamento da dor | |
| KR920701122A (ko) | 신규 이환식 아미노-치환 화합물 | |
| YU46300A (sh) | Farmaceutski aktivni morfolinol |